Estimation of anti-platelet drugs on human platelet aggregation with a novel whole blood aggregometer by a screen filtration pressure method

British Journal of Pharmacology

Volumn 133, Issue 8, 2001, Pages 1396-1404

  Sudo, T ^a   Ito, H ^a   Ozeki, Y ^a   Kimura, Y ^a  

^a OTSUKA PHARMACEUTICAL CO LTD   (Japan)

Author keywords

Anti platelet drug; PDE3; Platelet aggregation; Screen filtration pressure; Whole blood aggregation

Indexed keywords

ACETYLSALICYLIC ACID; ADENOSINE DIPHOSPHATE; ANTITHROMBOCYTIC AGENT; CILOSTAZOL; COLLAGEN; DIPYRIDAMOLE; THROMBIN RECEPTOR ACTIVATING PEPTIDE; TIROFIBAN;

ACCURACY; ANALYTIC METHOD; ARTICLE; DEVICE; DRUG DETERMINATION; DRUG EFFECT; FILTRATION; HUMAN; PRESSURE MEASUREMENT; PRIORITY JOURNAL; SCREEN FILTRATION PRESSURE; THROMBOCYTE AGGREGATION; WHOLE BLOOD AGGREGOMETER;

EID: 0034865993     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0704204     Document Type: Article

References (31)

1. The aggregation of blood platelets
2. The electronic aggregometer: A novel device for assessing platelet behavior in blood
3. Screen filtration pressure of blood - An evaluation
4. Platelet aggregate filtration pressure - A method of measuring platelet aggregation in whole blood
5. Role of adenosine uptake and metabolism by blood cells in the antiplatelet actions of dipyridamole, dilazep and nitrobenzylthioinosine
6. Cilostazol has beneficial effects in treatment of intermittent claudication. Results from a multicenter, randomized, prospective, double-blind trial
7. Ethanol-induced microaggregate formation in pig and rabbit blood. An in vitro study
8. Mechanism of the antiplatelet action of dipyridamole in whole blood: Modulation of adenosine concentration and activity
9. Dipyridamole inhibits platelet aggregation in whole blood
10. Activation and inhibition of blood platelet adenylate cyclase by adenosine or by 2-chloroadenosine
11. Pharmacological receptors on blood platelets
12. Comparion of the inhibitory effects of oral cilostazol, acetylsalicylic acid and ticropidine on platelet function ex vivo: Randomized, double-blind cross-over study
13. A new parameter for evaluating platelet aggregation in patients with chronic cerebral infarction
14. Difficulty in detecting inhibition of platelet aggregation by the impedance method
15. Effect of cilostazol on platelet aggregation and experimental thrombosis
16. Dipyridamole inhibition of adenosine metabolism in human blood
17. Effects of aspirin on platelet aggregation by a new type aggregometer of whole blood with screen filtration pressure method
18. Evaluation of the efficacy of antiplatelet drugs for ischemic heart disease patients
19. Differential antiplatelet efficacy for various GPIIb/IIIa antagonists: Role of plasma calcium levels
20. Characterization of whole blood aggregation with a new type of aggregometer by a screen filtration pressure method
21. MK-383 (L-700,462), a selective nonpeptide platelet glycoprotein IIb/IIIa antagonist, is active in man
22. 2+ on GP IIb-IIIa interactions with integrilin. Enhanced GP IIb-IIIa binding and inhibition of platelet aggregation by reductions in the concentration of ionized calcium in plasma anticoagulated with citrate
23. Role of extracellular ionized calcium in the in vitro assesment of GPIIb/IIIa receptor antagonists
24. Kinetics of adenosine uptake by erythrocytes, and the influence of dipyridamole
25. Enhancement of platelet sensitivity to ADP-aggregation by isometric exercise in arteriosclerotic patients and its prevention
26. Antiplatelet therapy
27. Inhibition of platelet aggregation and thromboxane production by low concentrations of aspirin in vitro
28. Potent effects of novel antiplatelet aggregatory cilostamide analogues on recombinant cyclic nucleotide phosphodiesterase isozyme activity
29. Alteration of blood on storage: Measurement of adhesiveness of "aging" platelets and leukocytes and their removal by filtration
30. Screen filtration pressure method and adhesiveness and aggregation of blood cells
31. Antiaggregatory effect of oral cilostazol and recovery of platelet aggregability in patients with cerebrovascular disease